ADCLEC.syn1 CAR T cells therapy (Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2024/10/16 16:10:42

Base Information

Drug NameADCLEC.syn1 CAR T cells therapy (Memorial Sloan-Kettering Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAdhesion G protein-coupled receptor E2 modulatorsC-Type lectin domain family 12 member A modulators

TargetsAdhesion G protein-coupled receptor E2C-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A